07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Clinical News

Bimagrumab: Phase II/III data

Top-line data from the double-blind, placebo-controlled, international Phase II/III RESILIENT trial in about 240 patients with sIBM showed that IV bimagrumab missed the primary endpoint. The trial evaluated 3 dose levels of bimagrumab. Novartis said...
03:07 , Apr 22, 2016 |  BC Extra  |  Clinical News

MorphoSys slides on bimagrumab miss

MorphoSys AG (Xetra:MOR) fell EUR 8.62 (17%) to EUR 41.78 on Thursday after bimagrumab ( BYM338) missed the primary endpoint in a Phase II/III trial to treat sporadic inclusion body myositis (sIBM). MorphoSys' partner Novartis...
01:53 , Mar 3, 2016 |  BC Extra  |  Financial News

MorphoSys gains on financial results, outlook

MorphoSys AG (Xetra:MOR) gained EUR 4.01 (11%) to EUR 41.72 on Wednesday after reporting 4Q15 and 2015 financial results, including revenues for the year that came in slightly above its guidance. MorphoSys reported EUR 106.2...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This year...
07:00 , Sep 14, 2015 |  BioCentury  |  Strategy

Mind melding

Novartis AG's third neuroscience deal of the summer checks two boxes for the pharma by sharing the risk for a BACE inhibitor program and adding another late-stage program in neurology, all without increasing the pharma's...
07:00 , Aug 21, 2014 |  BC Innovations  |  Cover Story

Fat chance for cancer cachexia

With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies could be better off turning to the cause of the wasting disease rather than targeting its symptoms....
07:00 , Apr 28, 2014 |  BioCentury  |  Strategy

Bigger is better

Novartis AG is showing every sign of continuing to think big. Ridding itself of low-performing businesses while doubling down on cancer will help the pharma increase its operating income in the short term and plug...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Clinical News

Bimagrumab: Phase II/III started

Novartis began a double-blind, placebo-controlled Phase II/III trial to evaluate 3 dose levels of IV bimagrumab in about 240 patients. MorphoSys said the start triggered an undisclosed milestone payment from Novartis under a 2007 deal...
07:00 , Sep 2, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Allenex AB (SSE:ALNX) gained SEK1.03 (48%) to SEK3.19 on Thursday after saying Mexico approved XM-ONE to detect human leukocyte antigen (HLA) and non-HLA antibodies between donor and recipient in organ transplantations. XM-ONE is an endothelial...